webmd.com
Can Marijuana or CBD Help With My Crohn's Disease?
Many people with Crohn’s try cannabis or CBD to ease symptoms. This article explains current evidence is limited: some symptom relief is possible, but there’s no clear proof it reduces gut inflammation and it may risk masking disease or prompting stopping needed medicines.
Adults with Crohn’s or IBD considering cannabis/CBD, caregivers, and gastroenterologists advising patients about symptom management and treatment risks.
What To Know
This WebMD article reviews what is known about marijuana (THC) and CBD for Crohn’s disease. It summarizes small clinical trial results (fewer than 100 people total), noting cannabis may help some symptoms (appetite, sleep, quality of life) but has not shown objective reduction in inflammation; CBD trials did not control disease.
The piece emphasizes risks of masking symptoms, stopping prescribed therapy, legal and workplace issues, and recommends discussing interest with your clinician and starting with low-THC formulations if pursuing use.
The evidence so far is limited and mixed: three small trials in Crohn’s are described, with only one (marijuana cigarettes) showing a possibility of inducing remission in a small subset; CBD trials did not. Studies are small, short, and use different cannabis formulations, so results are uncertain.
Cannabis may improve some symptoms (appetite, sleep, quality of life) but does not appear to reduce intestinal inflammation based on current evidence. That means it could mask symptoms and lead people to stop effective medical treatment, increasing risk of relapse, hospitalization, or surgery.
If you’re considering cannabis or CBD, talk with your gastroenterologist about goals and risks, check state laws and workplace policies, and consider starting with low THC under guidance rather than replacing prescribed IBD therapies.
Evidence rests on a few small, short trials and observational reports; formulations (THC vs CBD) differ and may affect outcomes. The article is patient-focused education, not new primary research; it recommends shared decision-making with clinicians and notes legal/workplace considerations.
